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ABSTRACT
Background The authors estimated trends in 1-year
case-fatality of stroke in relation to changes in vascular
risk management from 1997 to 2005.
Methods A cohort study was implemented using data
for 407 family practices in the UK General Practice
Research Database, including subjects with first acute
strokes between 1997 and 2005. One-year case-fatality
was estimated by year and sex. Rate ratios were
estimated using Poisson regression.
Results There were 19 143 women and 16 552 men who
had first acute strokes between 1997 and 2005. In
women, the 1-year case-fatality declined from 41.2% in
1997 to 29.2% in 2005. In men, the decline was from
29.2% in 1997 to 22.2% in 2005. The proportion of
general practices that prescribed antihypertensive drugs
to two-thirds or more of new patients with stroke
increased from 6% in 1997 to 48% in 2005, for statins
from 1% to 39% and for antiplatelet drugs from 11% to
39%. The rate ratio for 1-year mortality in 2005,
compared with 1997e1998, adjusted for age group, sex,
prevalent coronary heart disease, prevalent hypertension
and deprivation quintile was 0.79 (0.74 to 0.86,
p<0.001). After adjustment for antihypertensive, statin
and antiplatelet prescribing, the rate ratio was 1.29 (1.17
to 1.42).
Conclusions Reducing 1-year case-fatality after acute
stroke may be partly explained by increased prescribing
of antihypertensive, statin and antiplatelet drugs to
patients with recent strokes. However, these analyses
did not include measures of possible changes over time
in stroke severity or acute stroke management.
INTRODUCTION
Stroke is a major contributor to the global burden
of disease. Approximately 15.3 million strokes
occur worldwide each year, and stroke accounts for
approximately 10% of all deaths.1 In high-income
countries, mortality from stroke has been declining
for a number of years. In the UK, stroke mortality
halved over a 25-year period between 1979 and
2004.2
Changes in stroke incidence, as well as changes in
case-fatality, may be contributing to decreasing
stroke mortality.3 In high-income countries, stroke
incidence showed a general decline up to the early
1980s. Some studies suggest that stroke incidence
may have stabilised or increased since the late
1980s,4 but age-standardised data from the UK
suggest that the incidence of stroke continues to
decline.5 Stroke case-fatality is also decreasing. This
is evident in results from theWHOMonica study of
people aged 35e64 years, which found that changes
in stroke mortality appeared to result primarily
from changes in the case-fatality of stroke.6 7 A
report from Auckland, New Zealand found that 1-
year case-fatality following stroke declined from
45.6% in 1981e1982 to 30.2% in 2002e2003.3
Over the last two decades, there have been
important developments in the care of patients
with stroke. In the acute phase, the management of
acute stroke has been concentrated in stroke units
which may facilitate better outcomes.8 Manage-
ment of vascular risk contributes to preventing of
stroke, as well as reducing mortality and recurrent
vascular events subsequent to stroke onset. The
value of antihypertensive therapy,9 statin therapy10
and aspirin and antiplatelet therapy11 for reducing
recurrent vascular events and mortality has been
demonstrated in large randomised trials and meta-
analyses. These developments have been accompa-
nied by systematic attempts to improve the quality
of chronic illness care,12 and promote evidence-
based practice,13 leading to increased coverage of the
at-risk population with effective therapies.14
However, there is also evidence of poor-quality
practice and inadequate coverage of some groups at
risk.15 16
In the present study, we aimed to evaluate the
significance of vascular risk management for trends
in stroke survival in a sample with high geograph-
ical coverage and large numbers of cases. In this
study, we utilised data from electronic patient
records from UK family practices. We aimed to
estimate trends in 1-year survival following acute
stroke, to evaluate trends in prescribing for vascular
risk management and to determine whether
increasing coverage of vascular risk management
might be associated with trends in case-fatality.
METHODS
Ethics
The study represented an analysis of anonymised
data. The study protocol was approved by the
Independent Scientific Advisory Committee (ISAC)
of the Medicines and Healthcare products Regula-
tory Agency (MHRA) (ISAC Protocol No 07_027R).
Data source and subjects
The General Practice Research Database (GPRD) is
a large database that comprises the electronic
patient records from approximately 5% of UK
family practices.17 Practices contributing to the
GPRD are spread across the UK, including England,
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Wales, Scotland and Northern Ireland. There may be some
under-representation practices in the inner cities and in the most
affluent areas.17 However, the age and sex distributions of the
GPRD population are similar to those of the UK general popu-
lation.18 GPRD data are subject to quality checks and are
referred to as up to standard (UTS) when the data are of suffi-
ciently high quality to be used for research. Several studies have
shown that data for medical diagnoses recorded in GPRD have
satisfactory validity.19 20 Estimates for rates from GPRD are
consistent with those obtained from dedicated data collection
systems.21
For the present analyses, we selected subjects who had first
diagnoses of stroke between 1 January 1997 and 31 December
2006, and who had a minimum of 24 months UTS record prior
to the index stroke event. We did not evaluate recurrent strokes.
Initially, we utilised a set of 202 medical codes for stroke, derived
from the UK Office for National Statistics publication, Key
Health Statistics from General Practice.17 However, initial
analysis of the resulting sample of subjects revealed important
secular changes in the utilisation of specific codes. In particular,
there was a selective increase in the use of codes for ‘stroke
annual review’ and ‘stroke monitoring’ after 2003.22 This was
thought to be associated with contractual changes to family
practices associated with the Quality and Outcomes Frame-
work.23 The codes used in this paper were therefore reviewed and
restricted to 121 codes for cerebral infarction, cerebral haemor-
rhage, subarachnoid haemorrhage, ‘cerebral vascular accident’
and hemiplegia.22 The most frequently utilised index codes were
for ‘cerebral vascular accident,’ and it was not possible to
distinguish infarction from haemorrhage in the majority of
subjects. Data were extracted in August 2007, and as the
12-month follow-up was not complete for all subjects, subjects
diagnosed in 2006 were excluded.
Analysis
Numbers of strokes were tabulated by index year and gender.
The mean age at stroke onset date was estimated, as were the
proportions of subjects with coronary heart disease or hyper-
tension ever recorded before the stroke index date. Numbers of
deaths within 365 days of the stroke index date were enumer-
ated. The 1-year case-fatality was estimated from a time to event
analysis which allowed for the censoring that resulted from
patients transferring out of the practice or the end of the study
period being reached. Standardised case-fatality ratios (SCFR)
were estimated for quintiles of deprivation using all years for
reference.
Drug utilisation was estimated using information included on
all prescriptions issued to patients recorded in the GPRD
Therapy file. We evaluated three sets of drugs: antihypertensive
drugs including thiazide diuretics (British National Formulary,
BNF, section 2.2.1), potassium sparing diuretics (2.2.3) and their
combinations (2.2.4), b blockers (2.4), vasodilators (2.5.1),
centrally acting drugs (2.5.2), adrenergic neuron inhibiting drugs
(2.5.3), a-blockers (2.5.4), ACE inhibitors (2.5.5.1) and angio-
tensin receptor blockers (2.5.5.2) and calcium-channel blockers
(2.6.2); statins; and aspirin and antiplatelet drugs (BNF 2.9). For
each class of drugs, we evaluated whether the drugs were ever
prescribed before the stroke index date, or prescribed in the first
12 months after the stroke index date. We recognised that an
analysis at the individual patient level presented difficulties
because of confounding by indication, as well as length bias with
longer surviving subjects having a greater opportunity of being
prescribed drugs. We therefore implemented an analysis at the
level of the general practice. For each family practice and study
year, we estimated the proportion of patients with acute stroke
who were prescribed antihypertensive drugs, statins or anti-
platelet drugs. We classified practices by year, using an arbitrary
a priori classification, into those that prescribed the drug class of
interest to fewer than 33% of its patients with stroke, to between
33% and less than 66% of its patients with stroke, or to 66% of its
patients with stroke or greater.
We evaluated the association between drug utilisation and
case-fatality. We then fitted random-effects Poisson models,
using the ‘xtpoisson’ command in Stata V.10,24 deaths in the
first year following stroke were the dependent variables,
survival time to death, 1 year or end of study was the exposure,
with family practice as a random effect. We evaluated the
association of study year with 1-year case-fatality after
adjusting for fixed effects of age group, sex, deprivation quintile,
prevalent coronary heart disease or hypertension, and propor-
tions of subjects at each practice that were prescribed antihy-
pertensive drugs, statins or antiplatelet drugs.
RESULTS
There were 48 239 subjects, initially identified using 202 codes for
prevalent stroke with a minimum of 24 months’ stroke-free
record before the index date. From this set of cases, we selected
39 424 (82%) cases with restricted codes for acute stroke on the
index date as well as 293 (0.6%) cases in whom the index code
was not for acute stroke but in whom a code for acute stroke was
recorded within 30 days of the index date. After excluding 3708
subjects whose stroke diagnosis was in 2006, 276 whose death
date was recorded before the index date and 38 with uncertain
vital status, there were 35 695 subjects, including 19 143 women
and 16 552 men, for further analysis. The subjects were drawn
from 407 general practices; these included 239 contributing in
1997, increasing to 373 in 2005.
Table 1 shows the distribution of cases by gender and year of
study. The mean age at stroke was 70 years in men and 76 years
in women. There was weak evidence of a slight decline in age at
stroke in women and men. The proportion of stroke cases with
prevalent coronary heart disease was approximately 20% in
women and 26% in menwith no trend over time. The proportion
of subjects previously diagnosed as having hypertension
increased between 1997 and 2005, increasing from 40% to 56% in
women and from 37% to 48% in men. The 1-year case-fatality
after acute stroke declined between 1997 and 2005, from 41% to
29% in women and from 29% to 22% in men. There was strong
evidence of a linear trend by study year in both men and women.
Table 2 shows the SCFR for stroke by year and deprivation
quintile using data for all years as reference. In 1997, the SCFR
was 114 in the least deprived quintile and 118 in the most
deprived quintile. A decline in SCFR was observed across all
deprivation categories (p<0.001), and in 2005 the SCFRwas 83 in
the least deprived and 95 in the most deprived quintile. This
decline in SCFR was generally similar across all deprivation
quintiles.
Figure 1 shows the proportion of men and women in whom
the three classes of medications for vascular risk management
were prescribed by study year. Upper panels show the percentage
ever prescribed the drug class before stroke, while the lower
panels show the percentage prescribed drug class in the first
12 months after stroke. The proportion of subjects who were
prescribed antihypertensive medicines before stroke increased
from 65% in women and 54% in men in 1997, to 74% in women
and 64% in men in 2005. Prescribing of antihypertensive drugs in
the first 12 months after stroke increased from 53% of women
and 54% of men in 1997 to 74% of men and women in 2005.
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Statin prescribing before stroke increased, between 1997 and
2005, from 1% to 28% in women and from 4% to 30% in men.
Statin prescribing after stroke increased from 6% to 67% in
women and from 10% to 75% in men. Prescribing of antiplatelet
drugs before stroke increased from 33% to 49% in women and
from 35% to 48% in men. After stroke, prescribing of antiplatelet
drugs increased from 58% to 72% in women and from 62% to
73% in men. There was strong evidence of an increasing linear
trend for each drug class, in both sexes, before and after stroke
(p¼0.001 or smaller).
Table 3 shows the results of the practice-level analysis.
Prescribing of drug classes of interest to patients with recent
strokes varied widely between practices, with percentage
prescribed ranging from 0 to 100% at different practices in each
study year. Over the study period, there were substantial
increases in coverage of treatment with all three classes of
drugs. In 1997, 27% of practices prescribed antihypertensive
drugs to fewer than one-third of their patients with new
strokes, while only 6% prescribed antihypertensive drugs to
two-thirds or more of their new patients with stroke. By 2005,
48% of practices prescribed antihypertensive drugs to two-
thirds or more of their new patients with stroke, while only 6%
of practices prescribed antihypertensive drugs to fewer than
one-third of their new patients with stroke. In 1997, 97% of
practices prescribed statins to fewer than one-third of their new
patients with stroke; by 2005, 39% of practices prescribed
statins to more than two-thirds of their new patients with
stroke and 51% prescribed statins to between one and two-
thirds of new patients with stroke. For antiplatelet drugs,
practices prescribing to fewer than one-third of new patients
with stroke amounted to 24% of the sample in 1997 but only
7% in 2005; practices prescribing to more than two-thirds of
new patients with stroke increased from 11% in 1997 to 39% in
2005. Over all years, there was no association of deprivation
quintile with low prescribing of any drug class.
Table 4 shows the results of a Poisson regression analysis using
individual subject data. After adjusting for age group and sex, the
rate ratio for 1-year case-fatality in 2005, compared with 1-year
case-fatality in 1997e1998, was 0.73 (0.68 to 0.79, p<0.001).
Additional adjustment for deprivation quintile had negligible
influence on estimated associations. Further adjustment for
previously diagnosed hypertension and coronary heart disease
reduced the rate ratio to 0.79 (0.74 to 0.86, p<0.001). As there
was no trend in coronary heart disease, this observation suggests
that approximately 36% of the effect may be accounted for by
increased diagnosis of hypertension in primary care. After
adjusting for whether the patient was registered at a family
practice that prescribed antihypertensive drugs to a high
proportion of its patients with stroke, there was no association of
study year with 1-year survival. Further adjustment for propor-
tion prescribed statins or antiplatelet drugs yielded a positive
association of study year with increasing case-fatality.
Table 1 Characteristics of stroke subjects with 1-year case-fatality by year and gender
Year
Strokes Age (years)
Coronary heart
disease Hypertension 1-year case-fatality Standardised case-
death ratiosN Mean SD n % n % Deaths % 95% CI
Female
1997 1730 76.7 13.40 348 20.12 692 40.00 700 41.16 38.86 to 43.55 122 (113 to 131)
1998 1893 76.5 14.22 391 20.66 781 41.26 709 37.93 35.77 to 40.18 111 (103 to 119)
1999 2061 76.7 13.55 406 19.70 864 41.92 755 37.24 35.17 to 39.40 108 (101 to 116)
2000 2101 76.3 14.35 436 20.75 974 46.36 690 33.45 31.45 to 35.54 98 (91 to 105)
2001 2306 75.8 14.92 524 22.72 1100 47.70 726 32.16 30.27 to 34.14 95 (88 to 102)
2002 2371 75.4 14.83 490 20.67 1142 48.17 748 31.99 30.14 to 33.93 97 (90 to 104)
2003 2383 75.0 14.80 484 20.31 1196 50.19 727 30.85 29.02 to 32.76 96 (89 to 103)
2004 2212 74.8 15.54 437 19.76 1162 52.53 639 29.29 27.43 to 31.26 90 (83 to 97)
2005 2086 75.1 14.88 399 19.13 1175 56.33 602 29.24 27.33 to 31.26 89 (82 to 96)
p Value <0.001 0.519 <0.001 <0.001
Male
1997 1424 70.9 13.56 388 27.25 523 36.73 409 29.16 26.86 to 31.62 114 (103 to 125)
1998 1610 71.3 13.46 405 25.16 613 38.07 458 28.81 26.65 to 31.11 112 (102 to 122)
1999 1683 70.3 13.93 400 23.77 655 38.92 443 26.75 24.68 to 28.95 106 (96 to 116)
2000 1760 70.9 13.58 483 27.44 729 41.42 453 26.14 24.13 to 28.28 102 (93 to 112)
2001 1976 70.6 13.66 535 27.07 815 41.24 478 24.59 22.74 to 26.58 97 (89 to 106)
2002 2109 71.0 13.88 549 26.03 919 43.58 501 24.09 22.30 to 25.99 94 (86 to 102)
2003 2122 70.6 13.97 543 25.59 971 45.76 534 25.50 23.69 to 27.43 102 (94 to 111)
2004 2043 70.2 14.59 515 25.21 913 44.69 452 22.38 20.62 to 24.27 89 (81 to 98)
2005 1825 69.6 14.82 424 23.23 868 47.56 399 22.17 20.31 to 24.16 89 (80 to 98)
p value 0.036 0.261 <0.001 <0.001 <0.001
N, row total; n, frequency; p value, test for linear trend by study year.
Table 2 Standardised case-fatality ratio by year and practice
deprivation quintile
Year
Practice deprivation quintile
Least
deprived 2 3 4
Most
deprived
1997 114 118 121 122 118
1998 100 105 111 120 113
1999 106 103 100 116 108
2000 95 98 97 109 98
2001 88 103 89 99 101
2002 92 96 92 103 98
2003 96 98 97 106 96
2004 88 81 93 93 90
2005 83 88 85 95 95
Figures are standardised case-fatality ratios. Data for all years were used for reference.
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DISCUSSION
Main findings of this study
This study reveals a striking decrease in the 1-year case-fatality
of subjects diagnosed as having acute stroke in UK primary care
between 1997 and 2005. There was an absolute decrease in
1-year case-fatality of 11.8% for women and 6.7% for men, but
the relative decrease since 1997 was 28.8% for women and
23.2% for men. There were only minor changes in case mix,
including age and prevalent coronary heart disease, during the
period. However, there were major changes in prescribing of
medicines that modify vascular risk including antihypertensive
drugs, statins and aspirin and antiplatelet therapy. The decline
in case-fatality appeared to be explained by an increase in the
numbers of practices entering the higher prescribing categories
over time. While we cannot exclude bias from confounding,
these observations suggest that increasing coverage of the
population at risk with effective therapies that reduce vascular
risk may be one factor contributing to the decline in 1-year
case-fatality of acute stroke. These results provide indirect
evidence to support strategies that encourage more
intensive management of vascular risk in people who have had
strokes.25 26
Limitations of this study
Previous reports of trends in case-fatality of stroke have gener-
ally been from stroke registers. The strengths and limitations of
data from primary care databases differ from those of stroke
registers. This study had the strengths of a very large sample
drawn from a large number of general practices throughout the
UK. The study was not located in a single area and, by
encompassing different contexts and levels of risk, should offer
good external validity. Data recorded into the GPRD are subject
to quality checks, and previous studies have provided evidence of
the validity of recorded information on diagnoses and drug
prescribing.18e20 A key advantage of utilising data from
a primary care database is the opportunity to link data on stroke
occurrence and mortality to clinical information concerning
comorbidity and coprescribing.
A limitation of these clinical data is that the type of stroke
was generally not well characterised with the majority of
strokes being recorded using codes that do not distinguish
haemorrhage from infarction. It is not possible to evaluate the
contribution of changes in stroke type to changes in case-
death. Lawlor et al35 suggested that trends may have differed
for haemorrhagic, compared with ischaemic stroke. Mortality
Figure 1 Prescription of
antihypertensive drugs, statins or
antiplatelet drugs ever prescribed before
stroke or in the first year after stroke by
year and sex. AHT, antihypertensive
drugs; APL, antiplatelet drugs. Circles,
women; triangles, men.
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Table 3 Practice-level analysis showing number of general practices (row per cent) that prescribed drug class to different proportions of new patients
with stroke in first year after stroke.
Year
Proportion of new patients with stroke at general practice prescribed drug class in first year after stroke
Antihypertensive drugs Statins Antiplatelet drugs
<33% 33e<66% 66e100% <33% 33e<66% 66e100% <33% 33e<66% 66e100%
1997 64 (27) 160 (69) 15 (6) 232 (97) 5 (2) 2 (1) 57 (24) 156 (65) 26 (11)
1998 58 (23) 169 (66) 30 (12) 243 (95) 11 (4) 3 (1) 39 (15) 170 (66) 48 (19)
1999 57 (21) 193 (70) 25 (9) 255 (93) 19 (7) 1 (0) 46 (17) 180 (65) 49 (18)
2000 46 (16) 189 (65) 58 (20) 240 (82) 46 (16) 7 (2) 34 (12) 192 (66) 67 (23)
2001 42 (13) 205 (64) 75 (23) 215 (67) 93 (29) 14 (4) 33 (10) 200 (62) 89 (28)
2002 25 (7) 196 (58) 119 (35) 134 (39) 175 (51) 31 (9) 21 (6) 190 (56) 129 (38)
2003 34 (9) 203 (56) 127 (35) 84 (23) 219 (60) 61 (17) 25 (7) 196 (54) 143 (39)
2004 24 (6) 204 (56) 142 (38) 52 (14) 216 (58) 102 (28) 30 (8) 193 (52) 147 (40)
2005 23 (6) 172 (46) 178 (48) 39 (10) 190 (51) 144 (39) 27 (7) 202 (54) 144 (39)
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from haemorrhagic stroke may have declined in England and
Wales throughout the 20th century, while mortality from
ischaemic stroke may have increased up to the 1970s before
declining.
Initial analyses for this study revealed changes over time in
the use of medical codes for diagnosis of stroke. In particular,
there was a substantial increase in the use of codes for ‘stroke
annual review’ and ‘stroke monitoring’ in the period 2003e2005.
When used as index codes for stroke, these were associated with
a low 1-year case-fatality rate of approximately 5%.22 We
therefore implemented a more stringent case definition for this
study by utilising a restricted set of codes that led to selection of
82% of the initial sample. Exclusion of codes that might not be
indicative of acute stroke events and which were associated with
low case-death is likely to have had the effect of making the
results of the present analyses more conservative than if all initial
cases were used.22
Many patients with stroke are initially admitted to hospital
and, if they have not been seen by their family practitioner,
may not have a stroke event recorded into their primary care
record until a later date after discharge from hospital. Stroke
diagnosis dates may therefore be recorded imprecisely, and
there might be a consistent bias towards later recording of
stroke onset in primary care and underestimation of case-fatality.
It is possible that this form of bias could contribute to
apparently decreasing case-fatality if hospitalisation for stroke
increased. However, as noted above, our estimates are very
similar to those obtained by Carter et al3 in a population-based
registry.
Longer survival following stroke presents greater opportunities
for prescription of medicines to reduce vascular risk when
compared with subjects who die soon after the stroke onset.
Therefore, instead of estimating the association between antihy-
pertensive prescribing and survival for each individual subject, we
evaluated the proportion of subjects prescribed drug classes of
interest at the practice at which subjects were registered.
Confounding by indication may exist if patients who are consid-
ered unlikely to survive are not prescribed secondary prevention
interventions. We also acknowledge the importance of unmea-
sured confounders, such as cigarette smoking, that may be
contributing to secular trends. We also recognise the relevance of
the ‘inverse care law,’ which suggests that individuals with the
greatest needs may be least likely to receive treatment.36 This
leads to an interpretation that secondary prevention interven-
tions will be more often prescribed to people with low mortality
risk. However, the substantial changes in the prescribing patterns
of family practices over time, and the limited impact of adjusting
for deprivation quintile, argue against this interpretation.
Table 4 Rate ratios (95% CI) for death within 1-year of stroke by period
Adjusted for age group
and sex (model 1)
Model 1 and deprivation
quintile (model 2)
Model 2 and prevalent
coronary heart disease and
hypertension (model 3)
Model 3 and
antihypertensive prescribing
category (model 4)
Model 4 and statin and
antiplatelet prescribing
category
1997e1998 Reference Reference Reference Reference Reference
1999e2000 0.90 (0.85 to 0.95) 0.90 (0.85 to 0.95) 0.93 (0.88 to 0.99) 0.98 (0.92 to 1.04) 1.02 (0.96 to 1.09)
2001e2002 0.80 (0.75 to 0.85) 0.80 (0.75 to 0.85) 0.84 (0.79 to 0.89) 0.95 (0.89 to 1.01) 1.05 (0.99 to 1.12)
2003e2004 0.79 (0.74 to 0.84) 0.79 (0.74 to 0.84) 0.84 (0.79 to 0.89) 1.01 (0.95 to 1.08) 1.24 (1.15 to 1.34)
2005 0.73 (0.68 to 0.79) 0.74 (0.68 to 0.80) 0.79 (0.74 to 0.86) 1.03 (0.95 to 1.11) 1.29 (1.17 to 1.42)
p Value* <0.001 <0.001 <0.001 0.461 <0.001
*Test for linear trend.
What is already known on this topic
Reports from stroke registries have provided evidence of declining short-term case-fatality of stroke over a 20-year period during the 1980s
and 1990s in a diverse range of settings including Auckland, New Zealand,3 Dijon, France27 and rural Japan.28 However, in a hospital-based
study, Kleindorfer et al29 did not find any decrease in 30-day case-fatality of stroke between 1993e1994 and 1999. The population-based
OXVASC study in the UK also showed no change in 30-day case-fatality of stroke between 1981e1984 and 2002e2004.5 However, the
OXVASC study was based on a local population whose profile differs from that of other parts of the UK, being less mobile and more highly
educated. Studies of short-term case-fatality after stroke have focused on the prognostic importance of the acute management of stroke.
Thus, Carter et al3 suggested that increased hospital utilisation, and use of neuroimaging to facilitate appropriate management, were
important in contributing to the decline in 28-day case-fatality of stroke in Auckland, New Zealand. Saposnik et al30 found that failure to use
antithrombotic drugs in hospital, and lack of assessment by a stroke team, were important in determining both the short- and long-term
prognosis. There are fewer data available on trends in 1-year case-fatality from stroke, but the present data are consistent with those from
Auckland.3 Carter et al3 reported 1-year case-fatality for men of 31.9% in 1991/1992 and 25.6% in 2002e2003, while in women the
equivalent figures were 35.9% in 1991/1992 and 31.1% in 2002e2003. The results for the stroke register on Auckland for 2002e2003 are
very close to the estimates we obtained from UK primary care for the same year.
Systematic reviews have analysed evidence for the effectiveness of different therapies in the prevention of stroke, recurrent vascular
events and all-cause mortality. Law and colleagues9 concluded that the effectiveness of antihypertensive therapy in reducing stroke and
coronary heart disease, with a 41% reduction in stroke and 29% reduction in coronary heart disease, was similar in those with and without
previous stroke. While the benefits of antihypertensive therapy are considered to be gained in both haemorrhagic and ischaemic stroke,
treatment with either statins or antiplatelet drugs is more relevant to subjects with ischaemic stroke. Treatment with statins after stroke
reduces the risk of recurrent stroke by approximately 16% and major cardiovascular events by about 20%.10 Antiplatelet therapy after stroke
is associated with about 7% reduction in odds of death and 23% reduction in odds of recurrent ischaemic stroke.11
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